ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREVENTION OR TREATMENT OF SYSTEMIC DISEASES IN CATS
A method is described for the prophylaxis or treatment of hypertension in a cat in need of such treatment. The method includes administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to the cat, where the therapeutically effective amount of the sa...
Saved in:
Main Authors | , , , , , , |
---|---|
Format | Patent |
Language | English French |
Published |
10.01.2019
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | A method is described for the prophylaxis or treatment of hypertension in a cat in need of such treatment. The method includes administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to the cat, where the therapeutically effective amount of the sartan is administered in a daily dosage amount that is varied over a treatment period, the daily dosage amount of the sartan for a first period of time during the treatment period is 1.0 to 5.0 mg/kg of body weight, and the daily dosage amount of the sartan is decreased for a second period of time subsequent the first period of time during the treatment period.
L'invention concerne une méthode de prévention ou de traitement de l'hypertension chez un chat nécessitant un tel traitement. La méthode comprend l'administration d'une quantité thérapeutiquement efficace d'un antagoniste du récepteur 1 (AT-1) de l'angiotensine II (sartan) au chat, la quantité thérapeutiquement efficace du sartan étant administrée dans une quantité de dosage quotidienne qui varie sur une période de traitement, la quantité de dosage quotidien du sartan pendant une première période pendant la période de traitement est de 1,0 à 5,0 mg/kg de poids corporel, et la quantité de dosage quotidien du sartan est réduite pendant une seconde période de temps après la première période de temps pendant la période de traitement. |
---|---|
AbstractList | A method is described for the prophylaxis or treatment of hypertension in a cat in need of such treatment. The method includes administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to the cat, where the therapeutically effective amount of the sartan is administered in a daily dosage amount that is varied over a treatment period, the daily dosage amount of the sartan for a first period of time during the treatment period is 1.0 to 5.0 mg/kg of body weight, and the daily dosage amount of the sartan is decreased for a second period of time subsequent the first period of time during the treatment period.
L'invention concerne une méthode de prévention ou de traitement de l'hypertension chez un chat nécessitant un tel traitement. La méthode comprend l'administration d'une quantité thérapeutiquement efficace d'un antagoniste du récepteur 1 (AT-1) de l'angiotensine II (sartan) au chat, la quantité thérapeutiquement efficace du sartan étant administrée dans une quantité de dosage quotidienne qui varie sur une période de traitement, la quantité de dosage quotidien du sartan pendant une première période pendant la période de traitement est de 1,0 à 5,0 mg/kg de poids corporel, et la quantité de dosage quotidien du sartan est réduite pendant une seconde période de temps après la première période de temps pendant la période de traitement. |
Author | ANKE, Sven STARK, Marcus KLEY, Saskia TRAAS, Anne ALBRECHT, Balazs LEHNER, Stefan ZIMMERING, Tanja |
Author_xml | – fullname: ALBRECHT, Balazs – fullname: STARK, Marcus – fullname: TRAAS, Anne – fullname: ANKE, Sven – fullname: ZIMMERING, Tanja – fullname: LEHNER, Stefan – fullname: KLEY, Saskia |
BookMark | eNqNjLsKwkAQRbfQwtc_DFgLGy2i5bJOkikyKzuDYhWCrJUkgfj_GMEPsDqcw-Uuzazru7QwjeOSgiILMRBBRI8XDREcqysDkygUk2qFcIl4RVYKDN8S0Wk9OYQC5C6KNXk4k6ATFJjuvFNZm_mzfY1p8-PKbAtUX-3S0DdpHNpH6tK7uYW9zU7WHm2eu-zw3-oDjEY2BQ |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
DocumentTitleAlternate | ANTAGONISTE DU RÉCEPTEUR DE L'ANGIOTENSINE II POUR LA PRÉVENTION OU LE TRAITEMENT DE MALADIES SYSTÉMIQUES CHEZ LES CHATS |
ExternalDocumentID | WO2019008077A1 |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_WO2019008077A13 |
IEDL.DBID | EVB |
IngestDate | Fri Oct 04 05:03:16 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | English French |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_WO2019008077A13 |
Notes | Application Number: WO2018EP68189 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20190110&DB=EPODOC&CC=WO&NR=2019008077A1 |
ParticipantIDs | epo_espacenet_WO2019008077A1 |
PublicationCentury | 2000 |
PublicationDate | 20190110 |
PublicationDateYYYYMMDD | 2019-01-10 |
PublicationDate_xml | – month: 01 year: 2019 text: 20190110 day: 10 |
PublicationDecade | 2010 |
PublicationYear | 2019 |
RelatedCompanies | BOEHRINGER INGELHEIM VETMEDICA GMBH |
RelatedCompanies_xml | – name: BOEHRINGER INGELHEIM VETMEDICA GMBH |
Score | 3.1911006 |
Snippet | A method is described for the prophylaxis or treatment of hypertension in a cat in need of such treatment. The method includes administration of a... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
Title | ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREVENTION OR TREATMENT OF SYSTEMIC DISEASES IN CATS |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20190110&DB=EPODOC&locale=&CC=WO&NR=2019008077A1 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwEA9jivqmU_FjSkDpW7Fx_VgfhmRpulVYOto459Po10CQbriK_76Xuume9pbcwZEc3F1-l9wFofu54aRGt7DBxOe2bppFoieuSfTctpK8kztdI1HFySNhD1_M56k1baCPTS1M3Sf0u26OCBaVgb1Xtb9e_iexvPpt5eohfQfS4smXPU9bo2MV3Yihef0eH4deyDTGALdpIvrlwenIcShgpT11kFad9vmkr-pSlttBxT9G-2OQV1YnqFGULXTINn-vtdDBaH3lDcO19a1O0YyKQRBKLuJA4CDAEWd8LMMIUyHpIBRBLDGAOiyHHINmJ1yo_BNWlIhTqdr249DH8VsslfaxF8Scgj_FII5RGZ-hO59LNtRhpbM_xcxew-1tdc5Rs1yUxQXCJHc6JAVsl3dtM8-c9NGdAymzXOKmVkIuUXuXpKvd7Gt0pKYqEUGMNmpWn1_FDYTmKr2tNfoDWtuJ5g |
link.rule.ids | 230,309,786,891,25594,76903 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED-GivNNp-LH1IDSt2Lr-rE9DOnadK1u6WjjnE-lXTsQpBuu4r_vpW66p72FOziSH1wuv0vuAnA3U8xUaecGuvjMkDUtT-Sko6lyZuhJ1srMtpKI4uQhM7wX7WmiT2rwsa6FqfqEflfNEdGjpujvZbVfL_6TWE71tnJ5n76jaP7o8q4jrdixiG6qIjm9Lh0FTmBLto28TWLhrw5PR6ZpIVfaNZEUVmRp3BN1KYvNoOIewt4I7RXlEdTyogF1e_33WgP2h6srbxyuvG95DLHF-n7AKYt8RnyfhNSmIx6ExGLc6gfMjzhBUke4RwkiO6ZM5J-IkITU4qJtPwlcEr1FXKBPHD-iFu6nBM3ZFo9O4Nal3PZknGn8B0z8Gmwuq3UKO8W8yM-AqJnZUlPkdlnb0LKpmT50Ziia6h21k-qJeg7NbZYutqtvoO7x4SAe-Oz5Eg6ESiQlVKUJO-XnV36FYbpMryt0fwDy8YzQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=ANGIOTENSIN+II+RECEPTOR+ANTAGONIST+FOR+THE+PREVENTION+OR+TREATMENT+OF+SYSTEMIC+DISEASES+IN+CATS&rft.inventor=ALBRECHT%2C+Balazs&rft.inventor=STARK%2C+Marcus&rft.inventor=TRAAS%2C+Anne&rft.inventor=ANKE%2C+Sven&rft.inventor=ZIMMERING%2C+Tanja&rft.inventor=LEHNER%2C+Stefan&rft.inventor=KLEY%2C+Saskia&rft.date=2019-01-10&rft.externalDBID=A1&rft.externalDocID=WO2019008077A1 |